Toshio Shimizu
Overview
Explore the profile of Toshio Shimizu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
211
Citations
2618
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller K, Kao S, et al.
Front Oncol
. 2025 Feb;
14:1544394.
PMID: 39957803
[This corrects the article DOI: 10.3389/fonc.2024.1376551.].
2.
Hayato S, Hamuro L, Shimizu T, Yonemori K, Nishio S, Yunokawa M, et al.
J Clin Pharmacol
. 2025 Jan;
PMID: 39853764
The first-in-human, Phase 1 Study 101 showed antitumor activity and a tolerable safety profile of farletuzumab ecteribulin in Japanese patients with platinum-resistant ovarian and non-small cell lung cancer. A pharmacometric...
3.
Matsuda C, Nakayama Y, Haraguchi M, Morishima R, Itagaki Y, Bokuda K, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2025 Jan;
1-8.
PMID: 39850989
Objective: To investigate the impact of different ventilatory support options on opioid use among patients with amyotrophic lateral sclerosis (ALS). Methods: We retrospectively reviewed 889 consecutive patients with ALS and...
4.
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller K, Kao S, et al.
Front Oncol
. 2024 Nov;
14:1376551.
PMID: 39534099
Background: Transforming growth factor (TGF)-ß1 is a pleiotropic cytokine that can promote tumor growth and suppress antitumor immune responses. Latent TGF-ß1 associates with glycoprotein-A repetition predominant (GARP) on the surface...
5.
Takakura T, Akamatsu H, Washioka A, Murakami E, Shibaki R, Shimizu T, et al.
Respirol Case Rep
. 2024 Sep;
12(9):e01401.
PMID: 39220096
Several predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge. We report the...
6.
Wada T, Shimizu T, Asano Y, Kaneko T, Kawazoe T, Bokuda K, et al.
J Neurol
. 2024 Aug;
271(10):6715-6723.
PMID: 39158732
Background: The prognostic impact of dysphagia in multiple system atrophy (MSA) remains controversial. This study aimed to investigate the relationship between dysphagia severity and survival in MSA and to elucidate...
7.
Koyama T, Yonemori K, Shimizu T, Sato J, Kondo S, Sudo K, et al.
Cancer Res Commun
. 2024 Aug;
4(9):2349-2358.
PMID: 39140264
Purpose: The aim of the study was to evaluate the safety/tolerability and pharmacokinetics of simlukafusp alfa (FAP-IL2v), an immunocytokine containing an anti-fibroblast activation protein-α (FAP) antibody and an IL2 variant,...
8.
Wada T, Sugaya K, Asano Y, Nakata Y, Naito R, Kawazoe T, et al.
J Neurol Sci
. 2024 Jul;
463:123116.
PMID: 38981418
Objective: Dysphagia in multiple system atrophy (MSA) is life-threatening and is caused by parkinsonism with cerebellar ataxia as a contributing factor. The present study investigated the relationship between dysphagia severity...
9.
Peterlin P, Saada-Bouzid E, Moskovitz M, Pigneux A, Yuda J, Sinnollareddy M, et al.
Expert Rev Anticancer Ther
. 2024 Jul;
24(9):893-904.
PMID: 38946484
Background: ABBV-184, a novel survivin peptide-targeting T-cell receptor (TCR)/anti-CD3 bispecific protein, demonstrated preclinical T-cell activation and cytotoxicity toward HLA-A2:01-positive tumor lines. This first-in-human trial evaluated ABBV-184 monotherapy in patients with...
10.
Takakura T, Shimizu T, Yamamoto N
Jpn J Clin Oncol
. 2024 May;
54(8):837-846.
PMID: 38704241
Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds...